BC Innovations | Feb 5, 2019
Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer; melanoma; cancer Mouse studies suggest an mRNA immunotherapy based on IL-36γ, IL-23 and OX40L could help treat colorectal cancer, melanoma and other cancers, including those resistant to checkpoint inhibitors. The therapy consists...
BC Extra | Jan 31, 2019
Preclinical News

Moderna's triplet mRNA therapy treats checkpoint inhibitor-resistant tumors in mice

Moderna Inc. (NASDAQ:MRNA) published preclinical data Wednesday showing a triple mRNA combination product has efficacy against solid tumors, including those resistant to checkpoint inhibitors. The company's mRNA-2752 contains mRNAs encoding IL-23, IL-36γ and OX40L encapsulated...
Items per page:
1 - 2 of 2